5-氟-1,3-苯并间二氧杂环戊烯-4-胺 | 492444-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 5-氟-1,3-苯并间二氧杂环戊烯-4-胺
• 英文名称: 5-fluoro-1,3-benzodioxol-4-amine
• CAS: 492444-04-9
• 化学式: C₇H₆FNO₂
• mdl: MFCD09038122
• 分子量: 155.129
• InChiKey: HXEMSUWXUXWSHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  237.9±40.0 °C(Predicted)
• 密度：
  1.448±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  5-氟-1,3-苯并间二氧杂环戊烯-4-胺 在 N,N,N-trimethylbenzenemethanaminium dichloroiodate 、 calcium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以92.0%的产率得到4-amino-5-fluoro-7-iodo-1, 3-benzodioxole
  参考文献：
  名称：

  三并环类KAT6抑制剂

  摘要：

  本发明属于医药技术领域。特别地，本发明涉及一类三并环类KAT6抑制剂化合物、其药学上可接受的盐、其氘代物或其立体异构体，含有所述化合物、其药学上可接受的盐、其氘代物或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其氘代物或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其氘代物或其立体异构体在制备治疗和/或预防由KAT6介导的疾病及相关疾病的药物中的用途。

  公开号：

  CN116621859A
• 作为产物：
  描述：

  6-氟-2.3-二羟基苯甲酸 在 氢氧化钾 、 氯化亚砜 、 叠氮磷酸二苯酯 、 caesium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 5-氟-1,3-苯并间二氧杂环戊烯-4-胺
  参考文献：
  名称：

  Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

  摘要：

  Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

  DOI：

  10.1021/jm030317k

文献信息

• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• [EN] QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE QUINAZOLINE UTILISES DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2004004732A1

  公开（公告）日：2004-01-15

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中Z、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物时在固体肿瘤疾病的控制和/或治疗中的用途。
• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• PYRIMIDINE DERIVATIVES
  申请人：Kettle Jason Grant

  公开号：US20110046108A1

  公开（公告）日：2011-02-24

  The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
• Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK)
  作者：Christopher R. M. Asquith、James M. Bennett、Lianyong Su、Tuomo Laitinen、Jonathan M. Elkins、Julie E. Pickett、Carrow I. Wells、Zengbiao Li、Timothy M. Willson、William J. Zuercher

  DOI：10.3390/molecules24224016

  日期：——

  SGC-GAK-1 (1) is a potent, selective, cell-active chemical probe for cyclin G-associated kinase (GAK). However, 1 was rapidly metabolized in mouse liver microsomes by cytochrome P450-mediated oxidation, displaying rapid clearance in liver microsomes and in mice, which limited its utility in in vivo studies. Chemical modifications of 1 that improved metabolic stability, generally resulted in decreased GAK potency. The best analog in terms of GAK activity in cells was 6-bromo-N-(1H-indazol-6-yl)quinolin-4-amine (35) (IC50 = 1.4 μM), showing improved stability in liver microsomes while still maintaining a narrow spectrum activity across the kinome. As an alternative to scaffold modifications we also explored the use of the broad-spectrum cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) to decrease intrinsic clearance of aminoquinoline GAK inhibitors. Taken together, these approaches point towards the development of an in vivo chemical probe for the dark kinase GAK.

  SGC-GAK-1 (1)是一种针对cyclin G相关激酶（GAK）的有效、选择性、细胞活性化学探针。然而，在小鼠肝微粒体中，1通过细胞色素P450介导的氧化迅速代谢，导致在肝微粒体和小鼠中迅速清除，从而限制了其在体内研究中的实用性。对1的化学修饰改善了代谢稳定性，但通常导致GAK效力降低。在细胞中GAK活性方面效果最好的类似物是6-溴-N-(1H-吲唑-6-基)喹啉-4-胺（35）（IC50 = 1.4 μM），在肝微粒体中显示出改善的稳定性，同时仍保持着在激酶组中的狭谱活性。作为对骨架修饰的替代方案，我们还探索了广谱细胞色素P450抑制剂1-氨基苯并三唑（ABT）的使用，以降低氨基喹啉GAK抑制剂的内在清除率。综合考虑这些方法，指向了开发一种针对暗激酶GAK的体内化学探针的方向。